Celemics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Celemics develops tools and reagents that help scientists read, copy, and work with DNA, the genetic blueprint underlying drug discovery, disease diagnosis, and biological research.
Its products serve researchers and laboratories across modern medicine and molecular biology. The company focuses on integrating previously separate steps in the DNA-handling workflow, separation, sequencing, cloning, and synthesis, into a unified, high-throughput platform that reduces manual work and cost. It is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Celemics in five facts
What does Celemics do?
Celemics develops tools and reagents that help scientists read, copy, and work with DNA, the genetic blueprint underlying drug discovery, disease diagnosis, and biological research.
Where is Celemics listed and in which sector?
Celemics (Korean name: 셀레믹스) trades under KRX code 331920 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Celemics?
Its market capitalisation was US$85M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Celemics's latest annual revenue and operating profit?
For fiscal year 2025, Celemics reported revenue of US$4.4M, an operating loss of US$2.5M and a net loss of US$3M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 14.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Grant of stock optionsOct 6
- [Amended] Material event report (rights offering)
Celemics updated the terms of a private placement (third-party allotment) to raise US$7.43M, about 8.8% of its market value.
Capital raise · Sep 14 · 2 versions - Report on large shareholdings (5% rule) (standard)Sep 10
- Report on securities held by executives/major shareholdersSep 10
- Report on securities held by executives/major shareholdersSep 3
- Report on securities held by executives/major shareholdersSep 2
- Report on securities held by executives/major shareholdersSep 2
- Material management matter relevant to investment decisions
Celemics signed a license and supply agreement with Achieve Diagnostics, LLC (AchieveDx) of the United States on 2026-09-01, under which Celemics licenses its diagnostic technology and supplies diagnostic kits, carrying a three-year cumulative minimum commitment of USD 2,475,000 in royalties and USD 4,750,000 in kit purchases.
Supply contract · Sep 1 - [Amended] Material event report (rights offering)
Celemics updated the terms of a private placement (third-party allotment) to raise US$7.52M, about 10.3% of its market value.
Capital raise · Jun 24 - [Amended] Material event report (rights offering)
Celemics updated the terms of a private placement (third-party allotment) to raise US$7.56M, about 10.3% of its market value.
Capital raise · Jun 23 - [Amended] Material event report (rights offering)
Celemics updated the terms of a private placement (third-party allotment) to raise US$7.71M, about 10.3% of its market value.
Capital raise · May 21 - [Amended] Material event report (rights offering)
Celemics updated the terms of a private placement (third-party allotment) to raise US$2.88M, about 3.8% of its market value.
Capital raise · May 12 - [Amended] Material event report (convertible bonds)
Celemics updated the terms of convertible bonds to raise US$9.88M, about 13.0% of its market value.
Capital raise · Apr 29 - [Amended] Material event report (rights offering)
Celemics updated the terms of a private placement (third-party allotment) to raise US$2.9M, about 3.8% of its market value.
Capital raise · Apr 22 - [Amended] Material event report (rights offering)
Celemics updated the terms of a private placement (third-party allotment) to raise US$2.9M, about 3.8% of its market value.
Capital raise · Apr 17 - Material event report (rights offering)
Celemics disclosed a private placement (third-party allotment) to raise US$7.67M, about 10.3% of its market value.
Capital raise · Apr 1 - Material event report (convertible bonds)
Celemics disclosed convertible bonds to raise US$18M, about 23.9% of its market value.
Capital raise · Mar 31 - Change of largest shareholderOwnership change · Mar 12
- [Amended] Material event report (convertible bonds)
Celemics updated the terms of convertible bonds to raise US$2.75M, about 3.5% of its market value.
Capital raise · Mar 3 - [Amended] Share transfer agreement that will change the largest shareholder
Celemics's controlling stake is now set to change hands from an individual and 1 other to an individual, in a deal worth US$1.81M.
Ownership change · Feb 26 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Celemics reported consolidated results for FY2025: revenue of US$4.09M (−12.3% year on year), an operating loss of US$2.23M and a net loss of US$2.73M (from a profit a year earlier).
Earnings · Feb 19 - Material event report (rights offering)
Celemics disclosed a private placement (third-party allotment) to raise US$2.97M, about 3.8% of its market value.
Capital raise · Feb 4 - Material event report (convertible bonds)
Celemics disclosed convertible bonds to raise US$3.46M, about 4.4% of its market value.
Capital raise · Feb 4 - Share transfer agreement that will change the largest shareholder
Celemics's controlling stake is set to change hands from an individual and 1 other to an individual, in a deal worth US$1.78M.
Ownership change · Feb 3